Truist on Abivax (ABVX): 'We continue to see a robust opportunity'
Tweet Send to a Friend
Truist Securities analyst Greg Renza reiterated a Buy rating and $140.00 price target on Abivax (NASDAQ: ABVX).The analyst commented: "Recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


